NCT04199468View on ClinicalTrials.gov

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

June 21, 2022

Study Completion Date

June 21, 2022

Conditions
CannabisKetamine
Interventions
DRUG

Active Delta-9-THC

Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)

DRUG

Placebo Delta-9-THC

A placebo dose given intravenously (IV)

DRUG

Active Ketamine

Active Ketamine (0.2 mg/kg) given intravenously (IV)

DRUG

Placebo Ketamine

A placebo dose given intravenously (IV)

Trial Locations (1)

06516

VA Connecticut Healthcare System, West Haven

Sponsors
All Listed Sponsors
collaborator

Brain & Behavior Research Foundation

OTHER

lead

Yale University

OTHER